Physician profile
Keith Robert Brecher
NPI 1568457323
$3,697.12
in general payments reported to CMS, 2019-2025
30 companies · $941 in 2025
The $941 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $126 · 2021: $252 · 2022: $706 · 2023: $696 · 2024: $788 · 2025: $941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,424.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,006.61 | 2021-2025 | Qulipta, Ubrelvy |
| Pfizer INC. | $334.26 | 2019-2025 | |
| Lundbeck LLC | $279.76 | 2024-2025 | Vyepti |
| Emd Serono, INC. | $253.26 | 2022-2025 | Mavenclad |
| Lilly USA, LLC | $237.47 | 2022-2024 | Emgality, Reyvow, Amyvid |
| Sk Life Science, INC. | $199.64 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $197.12 | 2023-2024 | Aptiom |
| Novartis Pharmaceuticals Corporation | $192.71 | 2019-2022 | |
| Allergan, INC. | $113.78 | 2019-2022 | |
| Ucb, INC. | $99.05 | 2022-2023 | Nayzilam, Briviact |
| Axsome Therapeutics, INC. | $72.80 | 2023-2025 | Sunosi |
| Amgen INC. | $69.75 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $62.97 | 2023-2024 | Ultomiris |
| Eisai INC. | $57.04 | 2022 | |
| Neurelis, INC. | $47.49 | 2022-2025 | Valtoco |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $46.76 | 2025 | Ponvory |
| Teva Pharmaceuticals USA, INC. | $44.22 | 2024-2025 | Austedo Xr, Austedo Xr |
| Adamas Pharmaceuticals, INC. | $43.10 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $42.11 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $40.96 | 2021 | |
| Horizon Therapeutics Plc | $38.93 | 2022 | |
| Biogen, INC. | $36.36 | 2023-2024 | Skyclarys, Avonex, Tysabri |
| Mdd US Operations, LLC | $31.26 | 2024 | Gocovri |
| Jazz Pharmaceuticals INC. | $29.17 | 2024 | |
| Mallinckrodt Enterprises LLC | $24.54 | 2019 | |
| Genzyme Corporation | $23.46 | 2022 | |
| Impel Pharmaceuticals INC. | $20.31 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.34 | 2023 | Nuedexta |
| Scilex Pharmaceuticals INC. | $17.69 | 2022 | |
| Assertio Therapeutics, INC. | $16.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Brecher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.